Chengxin Shi

Chengxin Shi

Auto-generated profile, based on publicly available information

Chengxin Shi

Department of General Surgery, First Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710061, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Science Advances
Verified
Journal Article
Open access
CSChengxin Shi
Chengxin Shi
JDJianati Dawulieti
Jianati Dawulieti
FSFeiyu Shi
Feiyu Shi
CYChao Yang
Chao Yang
QQQian Qin
Qian Qin
JSJunjun She
Junjun She
A therapeutic strategy that targets multiple proinflammatory factors in inflammatory bowel disease (IBD) with minimal systemic side effects would be attractive. Here, we develop a drug-free, biodegradable nanomedicine that acts against IBD by scavenging proinflammatory cell-free DNA (cfDNA) and reactive oxygen species (ROS). Polyethylenimine (PEI) was conjugated to antioxidative diselenide-bridged mesoporous organosilica nanoparticles (MONs) to formulate nanoparticles (MON-PEI) that exhibited high cfDNA binding affinity and ROS-responsive degradation. In ulcerative colitis and Crohn’s disease mouse colitis models, orally administered MON-PEI accumulated preferentially in the inflamed colon and attenuated colonic and peritoneal inflammation by alleviating cfDNA- and ROS-mediated inflammatory responses, allowing a reduced dose frequency and ameliorating colitis even after delayed treatment. This work suggests a new nanomedicine strategy for IBD treatment.